Aclaris Therapeutics Announces $80 Million Private Placement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. AAPL
6. DELL
7. NIO
8. ENOV
9. AON
10. A

Go back to Aclaris Therapeutics Announces $80 Million Private Placement

Goldman Comments on Aclaris Therapeutics (ACRS), Shares up 33% Today, Up 245% Over Past 30 Days

November 19, 2024 11:07 AM EST

Goldman Comments on Aclaris Therapeutics (NASDAQ: ACRS)

The analyst comments "This morning, ACRS announced it has entered into a license agreement with Biosion for global rights (excluding China) to BSI-045B (also known as TQC2731), an anti-TSLP monoclonal antibody (mAb), and BSI-502, an anti-TSLP plus anti-IL4R... More

Leerink Partners Upgrades Aclaris Therapeutis (ACRS) to Outperform, Shares +20% in Premarket Session

November 19, 2024 7:06 AM EST

(Updated - November 19, 2024 7:19 AM EST)

Leerink Partners analyst Thomas J. Smith upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Market Perform to Outperform with a price target of $7.00 (from $2.00).

The analyst comments "We are upgrading ACRS to Outperform (from Market Perform) and raising our PT... More

Piper Sandler Upgrades Aclaris Therapeutis (ACRS) to Overweight, PT $13

November 18, 2024 2:54 PM EST

Piper Sandler analyst Christopher Raymond upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Neutral to Overweight with a price target of $13.00 (from $3.00).

The analyst comments "Upgrading ACRS shares to Overweight after what we see as a transformative deal to acquire two novel I&I... More

Stifel Reiterates Hold Rating on Aclaris Therapeutis (ACRS)

November 18, 2024 12:34 PM EST

Stifel analyst Alex Thompson reiterated a Hold rating and $3.00 price target on Aclaris Therapeutis (NASDAQ: ACRS)

The analyst comments "Aclaris announced a licensing agreement with Biosion to acquire ex-China rights to a clinical stage TSLP mAb (BSI-045B) and a preclinical TSLPxIL-4R bispecific (BSI-502). The... More